Detection of IgG4-Specific Autoantibodies in Rheumatoid Arthritis Serum Samples by Borogovac, Azra et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Senior Scholars Program School of Medicine 
2015-04-29 
Detection of IgG4-Specific Autoantibodies in Rheumatoid Arthritis 
Serum Samples 
Azra Borogovac 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/ssp 
 Part of the Amino Acids, Peptides, and Proteins Commons, Biological Factors Commons, Diagnosis 
Commons, Musculoskeletal Diseases Commons, Rheumatology Commons, and the Skin and Connective 
Tissue Diseases Commons 
Repository Citation 
Borogovac, Azra; Lahoud, Youmna; Weaver, Janice; Cooper, Sheldon M.; Rincon, Mercedes; Kay, Jonathan; 
and Gravallese, Ellen M., "Detection of IgG4-Specific Autoantibodies in Rheumatoid Arthritis Serum 
Samples" (2015). University of Massachusetts Medical School. Senior Scholars Program. Paper 192. 
https://escholarship.umassmed.edu/ssp/192 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Senior Scholars 
Program by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Detection of IgG4-Specific Autoantibodies in  
Rheumatoid Arthritis Serum Samples 
Azra Borogovac, BA1; Youmna Lahoud, MD1; Janice Weaver, CCRP1;  
Sheldon M. Cooper, MD2; Mercedes Rincon, PhD2; Jonathan Kay, MD1 and Ellen Gravallese, MD1 
1University of Massachusetts Medical School Worcester, MA 
2University of Vermont Medical Center, Burlington, VT 
Introduction 
Methods 
Results Objectives 
References 
Current Status 
• Rheumatoid arthritis (RA) is a chronic multi-system autoimmune 
disease characterized by inflammatory synovitis. 
 
• Autoantibodies, such as anti-citrullinated protein antibodies (ACPA) 
and rheumatoid factor (RF), are important serological markers that 
distinguish RA from other forms of inflammatory arthritis; yet many 
patients with RA do not have measurable ACPA or RF.   
 
• IgG4 is the second most abundant isotype of ACPA and RF, after 
IgG1; but, it is not detected by diagnostic assays typically available.  
 
• Patients deemed “sero-negative” by standard assays may actually 
have high titers of the IgG4-specific isotype of ACPA and RF[1]. 
• In a combined effort from 2 large medical centers, UMASS Memorial & UVM, over 100 subjects have been recruited, of whom 
data and sera have been collected. 
• IgG1- and IgG4-specific ACPA & RF testing is being performed by Dr. Mercedes Rincon at University of Vermont Medical Center. 
• Results from this large cross-sectional study should help to elucidate the role of IgG4-specific autoantibodies in the pathogenesis 
of RA and may aid in its early diagnosis . 
• In this cross-sectional study, we aim to enroll 1000 
patients with confirmed RA according to the 2010 
ACR/EULAR classification criteria. 
 
• We are collecting clinical information about each 
patient including demographics, current treatments, 
disease activity measures, laboratory test results, and 
radiographs.  
 
• Concurrently, we are collecting serum samples from 
each patient that will be analyzed for  
 1) Total levels of IgG4 & IgG1;  
 2) Total ACPA & RF;  
 3) Levels of IgG1- and IgG4-specific ACPA & RF;  
 4) Cytokine levels (TNF, IL-1, IL-6, IL-17, IFNγ, IL-21,  
        & G-CSF).  
• To date, we have recruited 102 RA patients with the following 
demographics [Table 2].  • To quantitate and compare levels of IgG1- and IgG4-specific ACPA and of IgG1- and IgG4-specific RF in 
patients with RA. 
• To correlate levels of IgG4-specific ACPA with disease 
activity, therapy, and serum cytokine levels. 
• To assess whether a diagnostic test that detects the 
IgG4 isotype of ACPA or of RF will allow earlier 
diagnosis of RA. 
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Background 
Table 2: Demographics characteristics of recruited subjects  
Age Mean ±SD 58.4 ± 12.4 years 
Sex Females  
Males 
68.6% (N=70) 
31.4% (N=32) 
Disease 
Activity 
Score using 
28 joints 
(DAS28) 
Mean ±SD 
 
Remission (DAS28 <2.6) 
Low Disease Activity (DAS28 >2.6 & <3.1) 
Mod Disease Activity (DAS 28 >3.2 & <5.1) 
High Disease Activity (DAS28 >5.1) 
3.67 ± 1.0 
 
12.2% (N=12) 
21.2% (N=21) 
61.2% (N=61) 
6.1%   (N=6) 
*Serologic 
testing  
(from medical 
record) 
RF + 
RF – 
 
ACPA + 
ACPA – 
 
RF+/ACPA+ 
RF-/ACPA+ 
RF+/ACPA- 
RF-/ACPA- 
54.0% (N=47) 
46.0% (N=40) 
 
70.0% (N=60) 
30.0% (N=27) 
 
49.4% (N=43) 
19.5% (N=17) 
4.5%   (N=4) 
27.9% (N=24) 
Medications DMARD therapy: 
  Methotrexate 
  Other DMARD 
 
Biologic therapy: 
  Anti-TNF biologics 
  Other biologics 
 
 
71.6% (N=73) 
26.5% (N=27) 
 
 
27.5% (N=28) 
12.7% (N=13) 
*Percentages exclude the 15 patients with unknown serologies. 
• Early initiation of therapy 
with Disease Modifying Anti-
Rheumatic Drugs 
(DMARDs), especially within 
the first 3 months of 
diagnosis, significantly 
reduces disease progression 
and morbidity of RA [2]. 
 
• ACPA and RF are important 
components of the 2010 
American College of 
Rheumatology/European 
League Against 
Rheumatism, classification 
criteria for early diagnosis of 
RA [3]. 
 
 • IgG4 autoantibodies contribute to the pathogenesis of autoimmune 
disease, but their specific roles have not yet been elucidated.  
 
• A recent study has shown that patients who lack IgG1-specific 
ACPA, and thus test negative for “total” IgG ACPA, have detectible 
IgG4-specific ACPA[1]. 
 
• Treatment with tocilizumab, a humanized anti-IL-6 receptor 
monoclonal Ab, markedly decreases levels of IgG4-specific ACPA, 
but does not affect “total” ACPA or IgG1-specific ACPA[1].  
 
Table 1: 2012 ACR/EULAR 
classification Criteria for RA 
 
Score 
Joint involvement: 
  1 large joint 
  2-10 large joints 
  1-3 small joints 
  4-10 small joints 
  >10 joints (at least 1 small joint) 
 
1 
2 
3 
4 
5 
Serology:  
  RF- and ACPA- 
  Low + RF or low + ACPA 
  High +RF or high +ACPA 
 
0 
2 
3 
Acute Phase Reactants: 
  Normal CRP and normal ESR 
  Abnormal CRP or abnormal ESR 
 
0 
1 
Duration of symptoms: 
  <6 weeks 
  ≥6 weeks 
 
0 
1 
Score of ≥6 /10 indicates definite RA 
